Backed by Nikhil Kamath’s NKSquared, the Bengaluru-based startup is betting on personalised healthcare with biomarkers, imaging, and AI for early risk detection.
Biopeak, a healthtech startup focused on longevity and precision healthcare, has secured $2.7 Mn (INR 24.8 Cr) in a fresh funding round led by Nikhil Kamath’s VC firm NKSquared, an existing investor in the startup.
Founded in 2024 by Rishi Pardal and Shiva Subramanian, Biopeak combines cellular diagnostics, AI, and advanced imaging to offer hyper-personalised care aimed at long-term vitality. The new capital will power its next phase of growth, including:
- A flagship longevity centre in Bengaluru
- Team expansion and specialist hiring
- Diagnostic and clinic footprint scale-up
- Deeper investment into AI models, research infrastructure, and clinical governance
Precision Health for the Longevity Economy
Biopeak’s technology maps an individual’s internal health state using a layered data approach that includes:
- 130+ biomarker blood panels
- Genetic and epigenetic testing
- Microbiome mapping (gut and oral)
- Hormonal rhythms and cortisol profiling
- Whole-exome functional genomics
- High-resolution MRI, CT, DXA, ECHO, and Carotid IMT imaging
These are then processed using AI algorithms to generate predictive health insights, early risk alerts, and lifestyle-personalised protocols.
“We’re not in the sick-care business. We’re building tools for healthspan enhancement—before symptoms appear,” a Biopeak spokesperson said.
Contextualised Care for South Asians
Biopeak’s strength lies in regional contextualisation. By partnering with institutions like IISc and Longevity India, it fine-tunes its data models for South Asian genetic and environmental factors.
This makes its insights more relevant for Indian populations, particularly in early detection of silent degenerative trends and chronic conditions often underdiagnosed in standard care.
Its core user base today includes:
- Young professionals
- Affluent individuals, particularly women
- Consumers looking for skin, gut, and neuro-longevity insights
Growing Investor Interest in Longevity Startups
The funding follows Biopeak’s $1.4 Mn raise in August 2024, part of a $3.5 Mn seed round led by Accel’s Prashanth Prakash, with participation from Claypond Capital and other angels.
The startup’s momentum reflects a broader investor shift into precision and preventive healthcare:
- Temple, founded by Deepinder Goyal, is exploring brain and oxygen tracking wearables
- Startups like Ultrahuman, Gabit, Noise, and FITTR are competing in health-focused smart rings and wearables
- Sychedelic launched neuromodulation-based headphones for sleep and stress
- 4baseCare recently raised $9.3 Mn to enhance oncology-focused AI diagnostics using genomic-lifestyle data fusion
What’s Next for Biopeak?
Armed with fresh capital, Biopeak will now:
- Launch a next-gen flagship clinic in Bengaluru
- Scale its clinical advisor network
- Deepen its AI and imaging stack, likely expanding use cases into predictive chronic care, biological aging metrics, and fertility health
In a crowded healthtech space, Biopeak’s bet is clear: precision, context, and longevity as a lifestyle—not just a medical necessity.
TL;DR
Healthtech startup Biopeak raised $2.7 Mn led by Nikhil Kamath’s NKSquared to expand its AI-powered longevity clinics. The company uses biomarker, genetic, and imaging data to deliver personalised health insights and plans to open a flagship Bengaluru centre while advancing its research and clinical footprint.
AI summary
- Biopeak raised $2.7 Mn from NKSquared to scale longevity clinics
- Offers AI-driven health insights using biomarkers and imaging
- Plans new flagship centre in Bengaluru, team expansion, and R&D investments
- Collaborates with IISc to contextualise data for South Asians
- Joins a growing list of startups focused on personalised and preventive care
